LabGenomics Co. Ltd (084650) - Total Assets
Based on the latest financial reports, LabGenomics Co. Ltd (084650) holds total assets worth ₩264.67 Billion KRW (≈ $179.36 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore LabGenomics Co. Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
LabGenomics Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of LabGenomics Co. Ltd for net asset value and shareholders' equity analysis.
LabGenomics Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
LabGenomics Co. Ltd's total assets of ₩264.67 Billion consist of 45.9% current assets and 54.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩-340.00 | 8.3% |
| Accounts Receivable | ₩37.96 Billion | 12.8% |
| Inventory | ₩3.74 Billion | 1.3% |
| Property, Plant & Equipment | ₩57.36 Billion | 19.4% |
| Intangible Assets | ₩24.37 Billion | 8.2% |
| Goodwill | ₩58.33 Billion | 19.7% |
Asset Composition Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 084650 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LabGenomics Co. Ltd's current assets represent 45.9% of total assets in 2024, a decrease from 61.6% in 2014.
- Cash Position: Cash and equivalents constituted 8.3% of total assets in 2024, down from 16.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 27.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 19.7% of total assets.
LabGenomics Co. Ltd Competitors by Total Assets
Key competitors of LabGenomics Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
SK Square Co Ltd
KO:402340
|
Korea | ₩27.25 Trillion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Hyundai Glovis
KO:086280
|
Korea | ₩19.87 Trillion |
|
Ecopro BM. Co. Ltd
KQ:247540
|
Korea | ₩4.62 Trillion |
|
DB Insurance Co Ltd
KO:005830
|
Korea | ₩72.11 Trillion |
|
HYBE Co. Ltd
KO:352820
|
Korea | ₩5.66 Trillion |
|
Hpsp Co Ltd
KQ:403870
|
Korea | ₩392.68 Billion |
|
TES Co. Ltd
KQ:095610
|
Korea | ₩538.50 Billion |
LabGenomics Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.83 | 1.95 | 3.50 |
| Quick Ratio | 1.77 | 1.91 | 3.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩51.09 Billion | ₩70.92 Billion | ₩62.51 Billion |
LabGenomics Co. Ltd - Advanced Valuation Insights
This section examines the relationship between LabGenomics Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | ₩295.66 Billion |
| Market Capitalization | $3.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values LabGenomics Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LabGenomics Co. Ltd's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual total assets of LabGenomics Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩295.66 Billion ≈ $200.37 Million |
-5.68% |
| 2023-12-31 | ₩313.46 Billion ≈ $212.43 Million |
+25.06% |
| 2022-12-31 | ₩250.65 Billion ≈ $169.86 Million |
+22.70% |
| 2021-12-31 | ₩204.29 Billion ≈ $138.44 Million |
+86.80% |
| 2020-12-31 | ₩109.36 Billion ≈ $74.11 Million |
+121.03% |
| 2019-12-31 | ₩49.48 Billion ≈ $33.53 Million |
+5.06% |
| 2018-12-31 | ₩47.09 Billion ≈ $31.92 Million |
+18.12% |
| 2017-12-31 | ₩39.87 Billion ≈ $27.02 Million |
-7.74% |
| 2016-12-31 | ₩43.21 Billion ≈ $29.28 Million |
+36.37% |
| 2015-12-31 | ₩31.69 Billion ≈ $21.47 Million |
+1.91% |
| 2014-12-31 | ₩31.09 Billion ≈ $21.07 Million |
-- |
About LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.